My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

92.77 UNCHANGED

Last Price Updated: 4:00 PM EST, Jan 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

59 60 Next >

How Cosmos Health’s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit

October 01, 2024

How Cosmos Health’s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit

Via News Direct

Is Summit Therapeutics Stock a Buy? ↗

September 30, 2024

Its alliance with a successful foreign biotech could be decisive for the stock.

Via The Motley Fool

Week In Review: Zenas Raises $259 Million In IPO ↗

September 28, 2024

It was a quiet week for biotech news in the Chinese market. Here is a brief overview of the notable events that occurred during this time. Zenas BioPharma staged a rare US biopharma IPO worth $259...

Via Talk Markets

Topics Initial Public Offering

Top Stock Reports For Toyota, AstraZeneca & Chubb ↗

September 26, 2024

Today's Research Daily features new research reports on 16 major stocks, including Toyota Motor Corp., AstraZeneca PLC, and Chubb Ltd., as well as two micro-cap stocks Air T, Inc. and Preformed Line...

Via Talk Markets

AstraZeneca Options Trading: A Deep Dive into Market Sentiment ↗

September 05, 2024

Via Benzinga

AstraZeneca's Top-Selling Cancer Drug Tagrisso Receives FDA Green Light For Another Lung Cancer Indication ↗

September 26, 2024

The FDA has approved AstraZeneca's Tagrisso for treating unresectable, Stage III EGFR-mutated non-small cell lung cancer, showcasing significant improvements in progression-free survival rates.

Via Benzinga

Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug ↗

September 23, 2024

Black Diamond Therapeutics reports promising initial Phase 2 data for BDTX-1535 in relapsed EGFR-mutant NSCLC patients. With a 36% objective response rate and encouraging durability, BDTX-1535 shows...

Via Benzinga

AstraZeneca Dips On Surprise Miss For Gilead-Rivaling Cancer Drug ↗

September 23, 2024

The company is still discussing the future for its Daiichi Sankyo-partnered ADC in metastatic breast cancer treatment.

Via Investor's Business Daily

Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients ↗

September 23, 2024

AstraZeneca released results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan, showing no statistically significant improvement in overall survival. The trial met its progression-free...

Via Benzinga

2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure? ↗

September 19, 2024

Pharma stock have been on the rise in the latter half of the year, but the 2024 election remains a wild card for shares.

Via Investor's Business Daily

2 Unstoppable S&P 500 Dividend Stocks to Buy Before They Beat the Market Again ↗

September 19, 2024

For over a decade, these two drugmakers consistently outperformed the benchmark index and could do it again.

Via The Motley Fool

Topics Stocks

Chinese Biotech BeiGene Labeled 'Unique Investment' As Analyst Confident In Lead Cancer Drug ↗

September 18, 2024

JMP Securities has initiated coverage on BeiGene highlighting the Chinese biotech company as a 'unique investment opportunity.' The firm's leading drug, Brukinsa (zanubrutinib), is emerging in the...

Via Benzinga

AstraZeneca's Asthma Drug Gets FDA Approval For Rare Disease Of Blood Vessel Inflammation ↗

September 18, 2024

The FDA has approved AstraZeneca's Fasenra for eosinophilic granulomatosis with polyangiitis based on Phase 3 MANDARA trial results. The drug showed similar remission rates to GSK's Nucala.

Via Benzinga

Time To Invest And Or Trade In Bio-Tech Stocks? ↗

September 13, 2024

Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help...

Via Talk Markets

Topics ETFs

Moderna To Slash $1.1 Billion From R&D Spending In Major Commercial Push ↗

September 12, 2024

The company says it's investment in R&D has paid off. Now, it needs to move its focus to launching new products.

Via Investor's Business Daily

AstraZeneca CEO Pascal Soriot Updates On Chinese Compliance Probe And Lung Cancer Drug Trial Results ↗

September 10, 2024

Chinese authorities have detained AstraZeneca employees amid a probe into potential data privacy breaches and unlicensed drug imports. CEO Pascal Soriot assures compliance with Chinese regulations and...

Via Benzinga

AstraZeneca's Investigational Cancer Drug Disappoints In Late-Stage Lung Cancer Trial ↗

September 10, 2024

AstraZeneca shared detailed results from the TROPION-Lung01 Phase 3 trial of datopotamab deruxtecan for non-small cell lung cancer, showing a clinically meaningful trend in overall survival compared to...

Via Benzinga

Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst ↗

September 09, 2024

HC Wainwright initiated coverage on Enliven Therapeutics, noting its innovative small molecules for tumor treatments. HC Wainwright gave a Buy rating with a $37 price target, projecting significant...

Via Benzinga

3 Market-Beating Stocks to Buy for Less Than $100 ↗

September 06, 2024

These stocks are all up more than 20% this year.

Via The Motley Fool

AstraZeneca In Trouble For Employee Detentions in China Over Illegal Activities ↗

September 05, 2024

Chinese police detain AstraZeneca employees over alleged data privacy breaches and unlicensed drug imports amid an anti-corruption drive.

Via Benzinga

Topics Law Enforcement

Reasonable Growth, Debt Levels, and a High ROIC Make ASTRAZENECA PLC-SPONS ADR (NASDAQ:AZN) Appealing to Quality Investors. ↗

September 04, 2024

Why ASTRAZENECA PLC-SPONS ADR (NASDAQ:AZN) Deserves Consideration as a Quality Investment.

Via Chartmill

EXCLUSIVE: Vivani Medical Reveals Positive Preclinical Liver Fat Results From Miniature GLP-1 Implant For Obesity ↗

September 04, 2024

Vivani Medical reports promising preclinical liver fat reduction results with its exenatide implant for obesity, showing potential as a differentiated treatment option. The LIBERATE-1 clinical trial is...

Via Benzinga

Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs ↗

September 03, 2024

Despite Medicare's first-ever negotiated drug prices under the Inflation Reduction Act, U.S. costs remain significantly higher than those in other wealthy nations, with some prices still more than...

Via Benzinga

Topics Economy

The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race ↗

August 29, 2024

The race to develop the next big obesity treatment is on with leaders Lilly and Novo trying to keep their top slots.

Via Investor's Business Daily

Biotech And Life Science Sector Update Summer Of 2024 ↗

August 29, 2024

It’s the slowest week of the year, we are at the market top and most earnings reports are good.

Via Talk Markets

AstraZeneca Threatens To Move Vaccine Production Amid Reduced State Support ↗

August 23, 2024

AstraZeneca may relocate its vaccine manufacturing site from Merseyside to Philadelphia as the UK government considers slashing state aid from £90 million to £40 million, jeopardizing Britain's life...

Via Benzinga

Biotech Bull Market: 3 Ways To Play It ↗

August 20, 2024

Although we are in the later stages of this bull market a cut in interest rates by the Fed should help biotech as you have seen from the recent rally.

Via Talk Markets

Topics Economy

Ozempic And Wegovy Linked to Increased Suicidal Thoughts In Observational Study, But Results Are Contested ↗

August 20, 2024

A recent study in JAMA Network Open raises concerns about a potential link between GLP-1 drugs Ozempic and Wegovy and an increased rate of suicidal thoughts after analyzing World Health Organization...

Via Benzinga

Johnson & Johnson Strikes $1.7B Deal To Acquire Heart-Tech Innovator V-Wave ↗

August 20, 2024

Johnson & Johnson to acquire V-Wave for $600 million with potential $1.1 billion in milestone payments. Deal boosts JNJ MedTech's cardiovascular portfolio. Also, FDA approves Rybrevant-Lazcluze combo...

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

August 19, 2024

Via Benzinga

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

59 60 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.